The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...
Every cycle has that one moment that splits winners from watchers. That’s the moment a project stops being “one to monitor” and becomes the one people wish ...
Ahead of the World Economic Forum‘s Annual Meeting in Davos, Switzerland, Fortune connected with Goldman Sachs’ global co-head of investment banking, Kim Posnett, for her outlook on the most urgent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results